The Uptake of Two Emerging Agents from Forest/AstraZeneca/Takeda and Trius Will Drive the... -- WALTHAM, Mass., June 28 /PRNewswire/ --.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of two emerging agents from Forest/AstraZeneca/Takeda and Trius will drive the methicillin-resistant Staphylococcus aureus (MRSA) drug market to increase from $631 million in 2009 to $752 million in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The Pharmacor 2010 findings from the topic entitled Methicillin-Resistant Staphylococcus Aureus find that Forest/AstraZeneca/Takeda's ceftaroline and Trius's torezolid will capture more than one-third of the MRSA drug market in 2019. A new drug application for ceftaroline for complicated skin and skin structure infections (cSSSIs) and community-acquired bacterial pneumonia was filed in the fourth quarter of 2009, and torezolid -- a second generation oxazolidinone -- is expected to begin Phase III clinical trials for cSSSI by end of 2010.